BlackRock Advisors LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 2.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,924,397 shares of the medical research company’s stock after buying an additional 85,974 shares during the period. BlackRock Advisors LLC owned approximately 0.52% of Amgen worth $597,097,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Arbor Wealth Management LLC raised its position in shares of Amgen by 124.5% in the second quarter. Arbor Wealth Management LLC now owns 8,418 shares of the medical research company’s stock worth $1,466,000 after buying an additional 4,668 shares during the last quarter. Virginia Retirement Systems ET AL purchased a new position in shares of Amgen during the second quarter worth $40,354,000. Vontobel Swiss Wealth Advisors AG purchased a new position in shares of Amgen during the second quarter worth $303,000. Mizuho Asset Management Co. Ltd. raised its position in shares of Amgen by 88.5% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 9,949 shares of the medical research company’s stock worth $1,514,000 after buying an additional 4,672 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Amgen by 1.5% in the second quarter. Vanguard Group Inc. now owns 46,679,076 shares of the medical research company’s stock worth $7,102,222,000 after buying an additional 673,247 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 167.34 on Tuesday. Amgen Inc. has a 12-month low of $138.06 and a 12-month high of $176.85. The stock has a market cap of $125.23 billion, a PE ratio of 17.12 and a beta of 0.94. The firm has a 50 day moving average price of $171.51 and a 200 day moving average price of $161.44.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping analysts’ consensus estimates of $2.74 by $0.10. The firm earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.57 earnings per share. On average, equities analysts expect that Amgen Inc. will post $11.36 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Wednesday, August 17th were paid a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.39%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is 40.90%.
A number of research firms recently commented on AMGN. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target for the company in a research report on Wednesday, August 3rd. Leerink Swann reissued a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Credit Suisse Group AG set a $206.00 price target on Amgen and gave the company a “buy” rating in a research report on Saturday, September 17th. Robert W. Baird reissued an “outperform” rating and issued a $157.00 price target on shares of Amgen in a research report on Friday, August 26th. Finally, Citigroup Inc. increased their price target on Amgen from $165.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 29th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $185.06.
In other news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.20% of the stock is owned by insiders.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.